FINWIRES · TerminalLIVE
FINWIRES

市場の動向:米国の規制強化を受け、中国は半導体製造装置の輸入先として東南アジアへの依存度を高めている。

-- 日経アジアは水曜日、中国の半導体製造装置輸入におけるマレーシアとシンガポールのシェアが2025年に急増し、米国を上回ったと報じた。 同報道によると、東南アジア諸国からの輸入額は過去最高を記録し、シンガポールからの輸入額は前年比17%超増の57億ドル、マレーシアからの輸入額は2倍以上の34億ドルに達した。 同報道は、ニーダム・アンド・カンパニーの半導体アナリスト、チャールズ・シー氏の発言を引用し、この増加は米国の半導体製造装置メーカーが米国以外の顧客に対応するため、東南アジアでの製造能力を拡大したことが要因だと指摘した。 一方、米国の輸入額は34%超減の約20億ドルとなり、8年ぶりの低水準となったと、同報道は中国税関のデータを引用して伝えた。 同報道によると、ドナルド・トランプ大統領による中国の半導体製造産業に対する関税引き上げと輸出規制強化が、この減速の一因となっている。 しかしながら、昨年も中国は米国の主要半導体製造装置メーカーにとって重要な収益源であり続けた、と同レポートは述べている。 日経アジアによると、中国にとって主要な半導体製造装置の出荷元別では、オランダと日本が依然として主要な海外供給元となっている。 一方、中国国内の半導体製造装置産業は、政府による国産装置の振興策を背景に著しい拡大を見せている、と同レポートは指摘している。 (マーケットチャッターのニュースは、世界中の市場専門家との会話に基づいて作成されています。この情報は信頼できる情報源に基づいていると考えられますが、噂や憶測が含まれる可能性があります。正確性は保証されません。)

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB